• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Single-Nucleotide Polymorphisms Related to Multiple Myeloma Risk: A Systematic Review and Meta-Analysis

by MM360 Staff | Apr 17, 2025 | Publications

Int J Mol Sci. 2025 Apr 4;26(7):3369. doi: 10.3390/ijms26073369. ABSTRACT Multiple myeloma ranks as the second most common hematopoietic malignancy in terms of both incidence and mortality. Prognostic stratification is critical for optimizing therapeutic strategies,...

ACIP Votes to Expand Lowering RSV Vaccine Recommendation Age to 50 for High-Risk Adults

by MM360 Staff | Apr 17, 2025 | Myeloma News

Source: Pharmacy Times articles The recommendations are not considered to be final until they are published in the Morbidity and Mortality Weekly Report. Read More

Dr. Grivas Highlights Three Practice-Changing Trials in Bladder Cancer

by MM360 Staff | Apr 17, 2025 | Uncategorized

Source: CureToday articles Dr. Petros Grivas discusses the importance of tailoring treatment decisions in bladder cancer based on data from three practice-changing phase 3 trials. Read More

Expert: Optimizing Transitions of Care for Heart Failure Patients

by MM360 Staff | Apr 17, 2025 | Myeloma News

Source: Pharmacy Times articles UPMC enhances heart failure patient care through integrated pharmacy and cardiology team collaboration. Read More

Antibody-Drug Conjugates Changed the Standard of Care in Bladder Cancer

by MM360 Staff | Apr 17, 2025 | Uncategorized

Source: CureToday articles Antibody-drug conjugates combined with immunotherapy have redefined the standard of care for advanced bladder cancer, replacing single-agent treatments. Read More
« Older Entries
Next Entries »

Recent Content

  • Renowned Breast Cancer Physician-Scientist Dr. Hope S. Rugo to Lead City of Hope’s Women’s Cancers Program
  • Measles Cases Climb to 800 in United States as Outbreak Spreads Across Borders
  • Reassessing Immunotherapy Use in Advanced Renal Cell Carcinoma
  • SPPCP 2025: Highlights and Can’t-Miss Sessions From the Virtual Conference on Pain and Palliative Care Pharmacy
  • First-Line Focus: Molecular Testing and Guideline-Directed Therapy in EGFR-Positive NSCLC
  • Momelotinib Shows Strong Efficacy in JAK-Exposed Myelofibrosis Patients
  • Recognizing Symptoms During Head and Neck Cancer Awareness Month
  • Overcoming Challenges in NSCLC Management From a Pharmacist’s Perspective
  • AI Tool May Better Predict Transplant Risk in Myelofibrosis
  • Study: Vision Impairment Signals Linked to Semaglutide Use
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT